These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 33551383

  • 1. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M, Hori Y, Kanno N, Iwasa N, Toyofuku T, Isayama N, Yoshikawa A, Akabane R, Sakatani A, Miyakawa H, Hsu HH, Miyagawa Y, Takemura N.
    J Vet Med Sci; 2021 Apr 24; 83(4):705-715. PubMed ID: 33551383
    [Abstract] [Full Text] [Related]

  • 2. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 24; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 3. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.
    Kanno N, Hori Y, Hidaka Y, Chikazawa S, Kanai K, Hoshi F, Itoh N.
    J Vet Med Sci; 2016 May 03; 78(4):535-42. PubMed ID: 26607133
    [Abstract] [Full Text] [Related]

  • 4. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS, Häggström J, Pedersen HD, Hansson K, Järvinen AK, Haukka J, Kvart C.
    J Vet Cardiol; 2014 Sep 03; 16(3):141-54. PubMed ID: 25130405
    [Abstract] [Full Text] [Related]

  • 5. Atrial natriuretic peptide vs. N-terminal-pro-atrial natriuretic peptide for the detection of left atrial dilatation in horses.
    van der Vekens N, Decloedt A, de Clercq D, Ven S, Sys S, van Loon G.
    Equine Vet J; 2016 Jan 03; 48(1):15-20. PubMed ID: 25257480
    [Abstract] [Full Text] [Related]

  • 6. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 03; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 7. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    J Vet Cardiol; 2012 Sep 03; 14(3):399-408. PubMed ID: 22858663
    [Abstract] [Full Text] [Related]

  • 8. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS, Yoon WK, Choi EW.
    Ir Vet J; 2023 Feb 08; 76(1):3. PubMed ID: 36755290
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG, Kamstrup TS, Pedersen HD, Häggström J.
    Vet J; 2009 May 08; 180(2):195-201. PubMed ID: 18675567
    [Abstract] [Full Text] [Related]

  • 10. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    Pol J Vet Sci; 2018 Dec 08; 21(4):673-680. PubMed ID: 30605282
    [Abstract] [Full Text] [Related]

  • 11. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Dec 08; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 12. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease.
    Häggström J, Hansson K, Kvart C, Pedersen HD, Vuolteenaho O, Olsson K.
    J Vet Cardiol; 2000 May 08; 2(1):7-16. PubMed ID: 19081325
    [Abstract] [Full Text] [Related]

  • 13. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 14. Distinguishing cardiac and noncardiac dyspnea in 48 dogs using plasma atrial natriuretic factor, B-type natriuretic factor, endothelin, and cardiac troponin-I.
    Prosek R, Sisson DD, Oyama MA, Solter PF.
    J Vet Intern Med; 2007 Nov 13; 21(2):238-42. PubMed ID: 17427383
    [Abstract] [Full Text] [Related]

  • 15. Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay.
    Fox PR, Oyama MA, Hezzell MJ, Rush JE, Nguyenba TP, DeFrancesco TC, Lehmkuhl LB, Kellihan HB, Bulmer B, Gordon SG, Cunningham SM, MacGregor J, Stepien RL, Lefbom B, Adin D, Lamb K.
    J Vet Intern Med; 2015 Jan 13; 29(1):171-9. PubMed ID: 25308881
    [Abstract] [Full Text] [Related]

  • 16. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 13; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 17. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J, Potocki M, Murray K, Breidthardt T, Ziller R, Mosimann T, Klima T, Hoeller R, Moehring B, Sou SM, Rubini Gimenez M, Morgenthaler NG, Mueller C.
    Heart; 2012 Oct 13; 98(20):1518-22. PubMed ID: 22865868
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
    Gaborit FS, Kistorp C, Kümler T, Hassager C, Tønder N, Iversen K, Hansen PM, Kamstrup PR, Faber J, Køber L, Schou M.
    Biomarkers; 2020 May 13; 25(3):248-259. PubMed ID: 32126847
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency.
    Takemura N, Toda N, Miyagawa Y, Asano K, Tejima K, Kanno N, Arisawa K, Kurita T, Nunokawa K, Hirakawa A, Tanaka S, Hirose H.
    J Vet Med Sci; 2009 Jul 13; 71(7):925-9. PubMed ID: 19652480
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.